Alex's questions to Cytokinetics Inc (CYTK) leadership • Q4 2024
Question
An analyst named Alex, on for Kripa Devarakonda at Truist Securities, asked about potential treatment bottlenecks due to insufficient monitoring equipment at cardiology centers and whether aficamten could be administered by a broader range of healthcare providers.
Answer
EVP & CCO Andrew Callos stated that based on their research, echo capacity is not currently a burden or limiting factor for patient treatment in the U.S., even in community settings. He noted that in Europe, treatment is more concentrated in hospitals which typically have capacity. President & CEO Robert I. Blum added that broader adoption is correlated with experience and education, and Cytokinetics aims to expand CMI use beyond centers of excellence, which would benefit the entire class.